Ampligen Exercise Tolerance - graph 1

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Source - doi:10.16966/2470-1009.103

Graph from study, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod.[1]

Key to graph[edit | edit source]

  • "Rintatolimod" - chemical name for Ampligen
  • "ET" - exercise tolerance measured by seconds on a treadmill using a modified Bruce exercise test (i.e., a cardiac diagnostic test which starts at a lower workload than the standard test and is typically used for elderly or sedentary patients)[2]
  • "ITT" - intent-to-treat population which is a statistical concept term used in studies to denote that the analysis includes every subject who was randomly placed in a treatment assignment group, and ignores noncompliance, protocol deviations, withdrawal, and anything that happens after randomization. It is considered a more accurate way to analyze data since noncompliance and protocol deviations would occur during clinical use.[3]

Interpretation of graph[edit | edit source]

  • Panel A - total study population retested at 40 weeks
  • Panel B - subset of study population retested at 40 weeks who could complete >9 minutes using a modified Bruce exercise test prior to receiving rintatolimod

See also[edit | edit source]

Ampligen

References[edit | edit source]

  1. Strayer, David R; Stouch, Bruce C; Stevens, Staci R.; Bateman, Lucinda; Lapp, Charles W; Peterson, Daniel L; Carter, William A; Mitchell, William M (Aug 8, 2015), "Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod" (PDF), Journal of Drug Research and Development, 1 (1), doi:10.16966/2470-1009.103 
  2. https://en.wikipedia.org/wiki/Bruce_protocol
  3. Gupta, SK (2011), "Intention-to-treat concept: A review.", Perspectives in Clinical Research, 2 (3): 109-112, doi:10.4103/2229-3485.83221 

chronic fatigue syndrome (CFS) - A fatigue-based illness. The term CFS was invented invented by the U.S. Centers for Disease Control as an replacement for myalgic encephalomyelitis (ME). Some view CFS as a neurological disease, others use the term for any unexplained long-term fatigue. Sometimes used as a the term as a synonym of myalgic encephalomyelitis, despite the different diagnostic criteria.

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

ME/CFS - An acronym that combines myalgic encephalomyelitis with chronic fatigue syndrome. Sometimes they are combined because people have trouble distinguishing one from the other. Sometimes they are combined because people see them as synonyms of each other.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.